Sporet levering verden over | Forventet 9–14 hverdage

Din kurv

Din indkøbskurv er tom

Begynd at browse

Gratis fragt på ordrer over €500.

Subtotal€0
Gå til betaling
HormonerTidlig klinisk

Kisspeptin-10

Publiceret forskning og dokumentationsgrundlag

Kisspeptin-10 (KP-10) is the C-terminal decapeptide fragment of the KISS1 gene product and an agonist at the kisspeptin receptor KISS1R (GPR54). Loss-of-function mutations in KISS1R were shown in 2003 to cause normosmic hypogonadotropic hypogonadism, establishing kisspeptin signalling as an upstream regulator of gonadotropin-releasing hormone secretion. Human administration studies, largely conducted at Imperial College London, have examined intravenous, subcutaneous and intranasal kisspeptin and its longer isoform kisspeptin-54 in healthy volunteers and in reproductive disorders. Kisspeptin is an investigational agent; no kisspeptin peptide is approved as a medicine in any major jurisdiction.

Kort fortalt
  • Kisspeptin-10 er et 10-aminosyre-fragment, der aktiverer KISS1R-receptoren.
  • Menneskestudier testede intravenøse, subkutane og intranasale former.
  • De fleste var små, akutte forsøg uden graviditets- eller langtidsdata.

42 studier · 14 siden 2023 · nyeste 2026

Undersøgelser citeret
42
Publiceret 2023+
14
Nyeste artikel
2026
Sidst gennemgået
okt. 2026

Tilbagevendende temaer i litteraturen

  • KISS1R/GPR54 agonist
  • GnRH pulse generator
  • gonadotropin secretion
  • KNDy neurons
  • hypothalamic-pituitary-gonadal axis
  • oocyte maturation trigger
  • hypoactive sexual desire disorder
  • functional hypothalamic amenorrhoea
  • central precocious puberty
  • kisspeptin-10 versus kisspeptin-54

Stofidentifikatorer

CAS
374675-21-5
PubChem
25240297

Kemisk identitet

Hvad Kisspeptin-10 er, kemisk.

Molekylformel
C63H83N17O14
Molekylvægt
1302.4 g/mol
CAS-nummer
374675-21-5
PubChem CID
25240297
Også skrevet som

Human metastin 45-54

Disse tal stammer fra PubChem-posten for denne forbindelse og beskriver den frie base. Lyofiliseret peptid leveres normalt som et acetat- eller trifluoroacetatsalt og indeholder restvand, så massen af pulver i et hætteglas er ikke den samme mængde, som molekylvægten ovenfor ville antyde. Kromatografisk renhed på et analysecertifikat løser heller ikke den forskel — Sådan læses et analysecertifikat forklarer hvorfor.

Evidensen

42 offentliggjorte studier.

Sorteret efter styrken i studiedesignet og derefter efter nyhed. Hver post linker til sin kildepost, så fundet kan kontrolleres mod artiklen i stedet for at tages på vores ord.

  1. 01Humant klinisk2026

    Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.

    Yeung AC, Phylactou M, Koysombat K, et al. · European Journal of Endocrinology · randomised controlled trial, chronic subcutaneous kisspeptin-10 administration in healthy men

    Continued subcutaneous kisspeptin-10 administration was associated with sustained stimulation of gonadotropin secretion across a 12-day dosing period, without the rapid loss of response reported with some continuous-exposure regimens.

  2. 02Humant klinisk2026

    Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.

    Naveed A, Lippincott MF, Stamou M, et al. · Hormones (Athens) · continuous intravenous kisspeptin infusion with frequent LH sampling in healthy men

    Continuous kisspeptin exposure produced time-dependent changes in luteinising hormone pulse characteristics rather than a uniform stimulatory effect, indicating that the gonadotropin response varies with the pattern of receptor exposure.

  3. 03Humant klinisk2026

    Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche.

    Banerjee AA, Bhanarkar SR, Kashikar S, et al. · Clinica Chimica Acta · diagnostic accuracy study in girls with central precocious puberty versus premature thelarche

    The ratio of circulating kisspeptin-10 to basal luteinising hormone discriminated central precocious puberty from premature thelarche more accurately than either measure alone.

  4. 04Humant klinisk2026

    Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans.

    Galbiati F, et al. · J Neuroendocrinol · single intravenous bolus of kisspeptin 112-121 (kisspeptin-10), twelve healthy adults (50% female)

    Circulating vasopressin did not change after kisspeptin, and levels were higher in men at all time points. The study did not support the intravenous bolus as a provocative test for vasopressin deficiency.

  5. 05Humant klinisk2025

    Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans.

    Mills EG, Silva MSB, Delli V, et al. · EBioMedicine · randomised controlled trial of intranasal kisspeptin in human volunteers, with supporting preclinical work

    Intranasal kisspeptin produced a rapid rise in circulating gonadotropins, demonstrating that a non-injectable route can engage the reproductive axis.

  6. 06Humant klinisk2025

    Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans.

    Mills EG, Thurston L, Yang L, et al. · The Journal of Clinical Endocrinology and Metabolism · randomised placebo-controlled trial in human volunteers

    Kisspeptin administration raised reproductive hormone concentrations but produced no measurable change in anxiety measures compared with placebo.

  7. 07Humant klinisk2025

    Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans.

    Galbiati F, et al. · Eur J Endocrinol · single intravenous bolus of kisspeptin 112-121 (kisspeptin-10), 12 healthy adults (50% female)

    Serum oxytocin rose 18.8% from baseline 10 minutes after kisspeptin, with a larger increase in men than in women (31.9% vs 5.7%).

  8. 08Humant klinisk2024

    Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical trials.

    Abbara A, Ufer M, Voors-Pette C, et al. · Fertility and Sterility · two randomised, placebo-controlled trials in healthy premenopausal women, kisspeptin receptor agonist MVT-602

    The long-acting KISS1R agonist MVT-602 produced a more prolonged luteinising hormone rise than native kisspeptin, in both unstimulated and ovarian-stimulated cycles.

  9. 09Humant klinisk2023

    Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.

    Mills EG, Ertl N, Wall MB, et al. · JAMA Network Open · randomised double-blind placebo-controlled crossover trial with functional MRI, men with hypoactive sexual desire disorder

    Kisspeptin administration modulated brain activity in regions associated with sexual processing and increased penile tumescence relative to placebo.

  10. 10Humant klinisk2023

    The effects of kisspeptin on food intake in women with overweight or obesity.

    Izzi-Engbeaya C, Choudhury MM, Patel B, et al. · Diabetes, Obesity and Metabolism · placebo-controlled administration study in women with overweight or obesity

    Kisspeptin administration did not produce a significant change in ad libitum food intake in women with overweight or obesity.

  11. 11Humant klinisk2022

    Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.

    Thurston L, et al. · JAMA Netw Open · randomized double-masked placebo-controlled crossover trial, n=32 premenopausal women with HSDD

    Kisspeptin-54 infusion modulated brain activity in response to erotic videos and facial attraction images; enhanced hippocampal and posterior cingulate responses correlated with sexual distress and reduced sexual aversion, and no adverse effects were reported.

  12. 12Humant klinisk2022

    Kisspeptin Overcomes GnRH Neuronal Suppression Secondary to Hyperprolactinemia in Humans.

    Hoskova K, et al. · J Clin Endocrinol Metab · two-visit study (baseline visit, then repeated intravenous boluses of kisspeptin 112-121, i.e. kisspeptin-10, over 10 hours), n=11 women with hyperprolactinaemia after washout of dopamine agonist and/or oral contraceptive

    Repeated kisspeptin boluses increased the number of LH pulses and mean LH without changing LH pulse amplitude, and 73% of women had an LH pulse within 30 minutes of the first dose. FSH and prolactin did not change significantly across the two visits.

  13. 13Humant klinisk2020

    Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.

    Skorupskaite K, et al. · Hum Reprod · randomised crossover study of intravenous kisspeptin-10 versus vehicle infusion, n=8 women with polycystic ovary syndrome given an NK3R antagonist for 7 days and 7 untreated women with PCOS

    Without antagonist pre-treatment, kisspeptin-10 increased LH secretion significantly, with a response that correlated with oestradiol. After the NK3R antagonist the LH response to kisspeptin-10 was preserved but no longer correlated with oestradiol, and FSH also rose.

  14. 14Humant klinisk2019

    Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men.

    Ullah H, et al. · Andrologia · single intravenous kisspeptin-10 bolus in healthy adult, middle-aged and older men, 120-minute sampling

    Plasma LH rose significantly after kisspeptin-10 in all age groups, whereas plasma testosterone rose significantly only in the adult group.

  15. 15Humant klinisk2019

    CHANGES IN IRISIN RELEASE IN RESPONSE TO PERIPHERAL KISSPEPTIN-10 ADMINISTRATION IN HEALTHY AND OBESE ADULT MEN.

    Shamas S, et al. · Acta Endocrinol (Buchar) · single peripheral kisspeptin-10 administration with sampling to 210 minutes, n=8 normal-weight and 8 obese men

    Plasma irisin rose significantly after kisspeptin-10 in both groups, with the highest mean levels at 210 minutes in normal-weight men and at 180 minutes in obese men.

  16. 16Humant klinisk2018

    Changes in the Responsiveness of the Hypothalamic-Pituitary-Gonadal Axis to Kisspeptin-10 Administration during Pubertal Transition in Boys.

    Nabi G, et al. · Int J Endocrinol · single intravenous kisspeptin-10 bolus in healthy boys at each of the 5 Tanner stages (n=5 per stage) and in 5 adult men, 120-minute sampling

    Kisspeptin-10 had no significant effect on LH or testosterone in boys at Tanner stages I-III. At stage IV testosterone but not LH rose, and at stage V both LH and testosterone rose significantly.

  17. 17Humant klinisk2018

    Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.

    Skorupskaite K, et al. · Neuroendocrinology · open study, eleven postmenopausal women given an NK3R antagonist for 7 days, with an intravenous kisspeptin-10 bolus during frequent blood sampling before and on the last day

    Kisspeptin-10 did not affect LH secretion with or without the NK3R antagonist. The antagonist lowered LH significantly and reduced hot-flash frequency in the 8 women who had hot flashes.

  18. 18Humant klinisk2017

    Kisspeptin modulates sexual and emotional brain processing in humans.

    Comninos AN, et al. · J Clin Invest · randomized placebo-controlled fMRI study, n=29 healthy young men

    Kisspeptin enhanced limbic brain activity in response to sexual and couple-bonding stimuli; this correlated with psychometric measures of reward, drive, mood and sexual aversion, and kisspeptin attenuated negative mood.

  19. 19Humant klinisk2017

    A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.

    Abbara A, et al. · Hum Reprod · kisspeptin-54 (the 54-amino-acid form), not kisspeptin-10: phase 2 randomised placebo-controlled trial, n=62 women at high risk of ovarian hyperstimulation syndrome undergoing IVF, randomised to a second subcutaneous kisspeptin-54 dose or saline after a first kisspeptin-54 trigger

    A higher proportion of women reached an oocyte yield of at least 60% with a second kisspeptin-54 dose (21/31, 71%) than with a single dose (14/31, 45%). Moderate OHSS occurred in 1 of 31 women in the single-dose group and none in the two-dose group.

  20. 20Humant klinisk2017

    Effect of gonadotropin-inhibitory hormone on luteinizing hormone secretion in humans.

    George JT, et al. · Clin Endocrinol (Oxf) · first-in-human study of gonadotropin-inhibitory hormone; four healthy men received an intravenous kisspeptin-10 bolus with simultaneous gonadotropin-inhibitory hormone or vehicle infusion (five postmenopausal women received the inhibitory hormone or vehicle alone)

    Kisspeptin-10-stimulated LH responses in men were not changed by co-administration of gonadotropin-inhibitory hormone, with near-identical 60-minute LH responses. No adverse events were reported.

  21. 21Humant klinisk2017

    Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men.

    Skorupskaite K, et al. · Clin Endocrinol (Oxf) · open-label study, n=6 healthy men given an NK3R antagonist for 7 days, with an intravenous kisspeptin-10 bolus before and on day 7

    Kisspeptin-10 stimulated LH secretion with similar responses before and during NK3R antagonist treatment, while the antagonist itself lowered LH, FSH and testosterone.

  22. 22Humant klinisk2016

    Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women.

    Skorupskaite K, et al. · J Clin Endocrinol Metab · randomised two-way crossover study of intravenous kisspeptin-10 versus vehicle infusion in healthy women with regular cycles during transdermal estradiol (10 pre-treated with an NK3R antagonist, 10 untreated controls)

    Kisspeptin-10 increased LH secretion during the inhibitory phase of estradiol feedback, and LH remained raised after the infusion ended. After NK3R antagonist pre-treatment the FSH response to kisspeptin-10 was larger, the LH rise was non-significant and shorter, and LH was lower at 48 hours.

  23. 23Humant klinisk2015

    Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men.

    Jayasena CN, Abbara A, Narayanaswamy S, et al. · Human Reproduction · comparative intravenous administration study in healthy men; kisspeptin-10 versus kisspeptin-54 versus GnRH

    Kisspeptin-10 and kisspeptin-54 both stimulated gonadotropin secretion, with kisspeptin-54 producing a more prolonged response than the shorter-acting kisspeptin-10.

  24. 24Humant klinisk2015

    Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.

    Abbara A, et al. · J Clin Endocrinol Metab · phase 2 randomized multi-dose trial, n=60 women at high risk of OHSS

    Oocyte maturation occurred in 95% of women; live birth rate per transfer was 45% across arms, and no woman developed moderate, severe or critical OHSS.

  25. 25Humant klinisk2014

    Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.

    Jayasena CN, et al. · J Clin Invest · open-label clinical trial, n=53 women undergoing IVF

    A single kisspeptin-54 injection after superovulation induced egg maturation at every tested dose; fertilisation and embryo transfer occurred in 92% of women, with biochemical and clinical pregnancy rates of 40% and 23%.

  26. 26Humant klinisk2014

    Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54.

    Jayasena CN, et al. · J Clin Endocrinol Metab · single-blinded dose-ranging infusion study, n=5 women with hypothalamic amenorrhoea (6 assessments each)

    Continuous kisspeptin-54 infusion increased LH pulsatility in every participant, with peak pulse number about 3-fold and pulse secretory mass about 6-fold higher than vehicle; peak responses occurred at different doses in each woman.

  27. 27Humant klinisk2013

    Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism.

    George JT, et al. · Clin Endocrinol (Oxf) · proof-of-concept intravenous study, five hypotestosteronaemic men with type 2 diabetes and seven age-matched healthy men, with an 11-hour infusion in four of the men with diabetes

    Intravenous kisspeptin-10 raised LH in both healthy men and men with type 2 diabetes, with comparable increments. During the 11-hour infusion in men with diabetes, LH, LH pulse frequency, pulsatile LH secretion and serum testosterone all increased.

  28. 28Humant klinisk2012

    Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback.

    George JT, et al. · Hum Reprod · experimental study of an intravenous kisspeptin-10 bolus, 10 women in the early follicular phase, 6 post-menopausal women and 8 women taking sex-steroid contraceptives

    Kisspeptin-10 stimulated LH secretion in follicular-phase, post-menopausal and progestogen-implant groups but not in women taking the combined pill. FSH rose significantly only in post-menopausal women, whose LH and FSH responses were the largest.

  29. 29Humant klinisk2012

    Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle.

    Chan YM, et al. · J Clin Endocrinol Metab · intravenous bolus of kisspeptin 112-121 (kisspeptin-10) in healthy women across the menstrual cycle: ten early follicular, three late follicular (preovulatory), 14 midluteal, plus four early-to-midfollicular women at a higher dose

    LH pulses followed kisspeptin in all luteal and preovulatory women but in only half of early follicular women, and the higher dose did not increase the early-to-midfollicular response. Kisspeptin did not appear to reset the GnRH pulse generator in women as it does in men.

  30. 30Humant klinisk2011

    The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.

    Jayasena CN, Nijher GM, Comninos AN, et al. · The Journal of Clinical Endocrinology and Metabolism · intravenous kisspeptin-10 administration in healthy men and women across menstrual cycle phases

    Kisspeptin-10 raised luteinising hormone in men, whereas the response in women depended on menstrual cycle phase, demonstrating sex-dimorphic sensitivity to the peptide.

  31. 31Humant klinisk2011

    Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

    George JT, et al. · J Clin Endocrinol Metab · dose-response and infusion study in healthy men (n=4-6 per experiment)

    Intravenous kisspeptin-10 boluses produced a rapid, dose-dependent LH rise with a smaller response at the highest bolus; continuous infusion increased LH, testosterone, LH pulse frequency and secretory burst mass.

  32. 32Humant klinisk2011

    Kisspeptin resets the hypothalamic GnRH clock in men.

    Chan YM, et al. · J Clin Endocrinol Metab · single intravenous bolus of the C-terminal decapeptide of kisspeptin (amino acids 112-121, i.e. kisspeptin-10) with frequent LH sampling, thirteen healthy men

    Kisspeptin induced an immediate LH pulse regardless of the timing of the previous endogenous pulse, and these induced pulses were on average larger than endogenous pulses. It also delayed the next endogenous pulse, consistent with a reset of the GnRH pulse generator.

  33. 33Humant klinisk2010

    Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.

    Jayasena CN, et al. · Clin Pharmacol Ther · kisspeptin-54 (the 54-amino-acid form), not kisspeptin-10: randomised comparison of two injection regimens and of 8 weeks of kisspeptin-54 versus saline, women with hypothalamic amenorrhoea

    With the more frequent regimen, LH responsiveness declined gradually and FSH responsiveness was nearly abolished by day 2, whereas the less frequent regimen caused only partial desensitisation. After 8 weeks of the less frequent regimen reproductive hormone levels were significantly higher than with saline, and no adverse effects were observed.

  34. 34Humant klinisk2009

    Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.

    Jayasena CN, et al. · J Clin Endocrinol Metab · kisspeptin-54 (the 54-amino-acid form), not kisspeptin-10: randomised double-blind parallel trial of subcutaneous kisspeptin-54 versus saline, n=5 per group women with hypothalamic amenorrhoea, 2 weeks

    On the first injection day kisspeptin-54 produced large rises in LH and FSH, but by the 14th injection day these responses were markedly reduced, indicating desensitisation. Responsiveness to GnRH was preserved, and LH pulsatility and ovarian ultrasound measures did not change.

  35. 35Humant klinisk2005

    Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.

    Dhillo WS, et al. · J Clin Endocrinol Metab · kisspeptin-54 (the 54-amino-acid form), not kisspeptin-10: double-blind placebo-controlled crossover study, n=6 healthy male volunteers, 90-minute intravenous infusion versus saline

    Kisspeptin-54 significantly increased plasma LH, FSH and testosterone compared with saline infusion. The plasma half-life of kisspeptin-54 was about 27.6 minutes.

  36. 36Humant klinisk2003

    The GPR54 gene as a regulator of puberty.

    Seminara SB, Messager S, Chatzidaki EE, et al. · The New England Journal of Medicine · genetic study of a consanguineous family with idiopathic hypogonadotropic hypogonadism, with mouse knockout confirmation

    Loss-of-function mutations in GPR54 (KISS1R) segregated with hypogonadotropic hypogonadism, and Gpr54-null mice showed a comparable phenotype, identifying the receptor as a gatekeeper of puberty.

  37. 37Humant klinisk2003

    Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54.

    de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. · Proceedings of the National Academy of Sciences of the United States of America · homozygosity mapping in a consanguineous family with normosmic hypogonadotropic hypogonadism

    A homozygous deletion in GPR54 was identified in affected family members, independently establishing KISS1R signalling as required for normal GnRH-driven reproductive function.

  38. 38Dyr in vivo2026

    Kisspeptin-10 Promotes Hormone Secretion, Ovarian Follicles Development and Fecundity via PI3K/AKT/ERK Signal Pathway in Mice.

    Suocheng W, Linglong X, Jingshuang G, Zhenya G, Yuan C. · Molecular Reproduction and Development · mice treated with kisspeptin-10

    Kisspeptin-10 treatment increased reproductive hormone secretion and follicular development in mice, with effects attributed to PI3K/AKT and ERK signalling.

  39. 39Gennemgang2026

    Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders.

    Pierret ACS, Patel AH, Daniels E, Comninos AN, Dhillo WS, Abbara A. · Andrology · narrative review of kisspeptin as a diagnostic stimulation test

    The review summarised evidence that kisspeptin administration probes GnRH neuronal function directly and reported its investigational use in distinguishing constitutional delay of puberty from congenital hypogonadotropic hypogonadism.

  40. 40Gennemgang2025

    Kisspeptin and neurokinin B: roles in reproductive health.

    Koysombat K, Tsoutsouki J, Patel AH, et al. · Physiological Reviews · comprehensive physiological review

    The review consolidated the KNDy neuron model in which kisspeptin, neurokinin B and dynorphin jointly shape GnRH pulse generation, and catalogued human administration data for kisspeptin-10 and kisspeptin-54.

  41. 41Gennemgang2024

    Kisspeptin in functional hypothalamic amenorrhea: Pathophysiology and therapeutic potential.

    Patel AH, Koysombat K, Pierret A, Young M, Comninos AN, Dhillo WS, Abbara A. · Annals of the New York Academy of Sciences · narrative review

    The review described reduced kisspeptin tone as a candidate mechanism in functional hypothalamic amenorrhoea and summarised early human data on kisspeptin administration restoring luteinising hormone pulsatility.

  42. 42Caserapport2017

    Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea.

    Millar RP, et al. · J Endocr Soc · exploratory vehicle-controlled study, two women with chronic hyperprolactinaemic amenorrhoea due to cabergoline-resistant microprolactinomas, 12-hour intravenous kisspeptin-10 infusion

    Kisspeptin-10 increased LH and FSH levels and LH pulses, and serum estradiol, testosterone and inhibin B also rose significantly.

Begrænsninger

Hvad denne evidens ikke fastslår.

Human kisspeptin studies have been predominantly acute, single-centre, small-sample administration experiments in healthy volunteers, with few randomised trials reporting clinical endpoints such as live birth, pregnancy or sustained symptomatic improvement. Much of the human clinical work used kisspeptin-54 rather than kisspeptin-10, long-term safety data are absent, and no kisspeptin peptide has regulatory approval for any indication.

Almindelige spørgsmål om forskningen.

What is Kisspeptin-10?

Kisspeptin-10 is a decapeptide — the shortest fully active fragment of the kisspeptin family encoded by the KISS1 gene. It is an agonist at KISS1R (formerly the orphan receptor GPR54), which sits upstream of GnRH neurons in the hypothalamus.

How does it differ from kisspeptin-54?

They share the C-terminal RF-amide motif required for receptor binding and act at the same receptor, but differ in length and in circulating profile. Much of the foundational human work used kisspeptin-54 by infusion, while the 2011 study on this page used kisspeptin-10 by bolus and by continuous infusion.

How does it differ from HCG?

They act at different levels of the reproductive axis. HCG acts directly at the gonadal LH/hCG receptor, bypassing the brain entirely. Kisspeptin-10 acts several steps higher, at KISS1R on hypothalamic GnRH neurons, so its downstream effect depends on the pituitary and gonadal machinery below it responding normally.

Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning, og intet studie opsummeret her skal læses som en anbefaling.